Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Wednesday, May 13, 2026

Snapshot: May 13, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Wed, May 13, 2026 Divergent Extreme

Extreme dispersion and divergent signals as mega-cap tech rallies while small caps flatline and micro stocks explode both directions on AI hype and earnings chaos.

60% Extreme single-stock volatility overwhelmed index direction today, with the top gainer (TDIC) soaring 877% on an AI partnership while the worst performer (WOK) cratered 59%, and 50 gainers averaging +55% against 50 losers averaging -24%, all on a day NASDAQ beat SPY by 1.2pp but Russell 2000 barely budged—a stock-pickers market par excellence where sector concentration broke down entirely.
25% Tech led NASDAQ's 1.20% outperformance while simultaneously dominating the losers list with 37% of declines, signaling a sharp internal rotation within the sector between AI beneficiaries (TDIC, QUCY, OUST) and legacy software names getting repriced (RVPH, BTM, WIX down 28-56%), leaving broad risk-off fears dormant as VIX dropped 0.67%.
15% Five debut gainers (QUCY, VELO, MEI, BESS, FRVO) and a three-day UBXG loser streak underscored a market hunting for fresh narratives, with news-grounded catalysts (earnings beats, strategic partnerships, offerings) driving roughly half the top 50 moves while the other half remained unexplained by public announcements, suggesting either delayed reporting or pure technical/retail trading in depressed micro-caps.

Technology drove 37% of losers 5 names returned after long absences UBXG · 3-day losers streak QUCY — first appearance VELO — first appearance

Market Regime

Wed, May 13, 2026 Risk-On conf: high macro · prototype

+27

Tailwind −100 … +100 · + tailwind / − headwind

VIX17.9 p60 Drawdown0.0% Held23d · extended SinceApr 13

Top drivers: S&P vs 50d avg ▲ S&P vs 20d avg ▲ S&P 20d return ▲

processId: history-market-regime

Market Indexes

Wed, May 13, 2026 4

S&P 500

7,444.88

+43.92

+0.59%

NASDAQ Composite

26,402.34

+314.14

+1.20%

Russell 2000

2,843.93

+1.10

+0.04%

VIX

17.87

−0.12

-0.67%

Biggest Gainers

Wed, May 13, 2026 50

TDIC

Dreamland Limited Class A Ordinary SharesCommunication Services

$23.05+$20.69

+876.7%

NASDAQ · Mkt cap $4.0 M

Dreamland announced a strategic AI partnership through subsidiary Trendic International to develop an intelligent image library platform with facial recognition and cloud infrastructure, catalyzing the stock's massive 876% gain as investors bet on AI-driven expansion beyond its core event managem…

On May 12, Dreamland Limited announced a memorandum of understanding with LinkFung Innovation Limited to jointly explore development and deployment of an AI-powered intelligent image library platform featuring facial recognition, cloud infrastructure, and AI-driven capabilities. This represents a material strategic pivot from the company's traditional event management focus into artificial intelligence and image processing—a high-growth sector. The timing of the announcement on May 12 followed by the stock's explosive move on May 13 suggests investor enthusiasm for this diversification into AI. The 876% single-day gain is extreme and likely reflects either a combination of pent-up interest in a low-liquidity or previously underperforming stock, the announcement's perceived significance relative to the company's market cap, or both. While the headlines do not provide financial details, partnership scope, or revenue projections, the AI angle in a strong sector environment appears to be the primary catalyst.

QUCY

Mainz Biomed N.V.Healthcare

$1.35+$1.03

+318.2%

NASDAQ · Mkt cap $15 M

Quantum Cyber announced an exclusive IP license agreement for an autonomous drone platform tied to a potential $55 billion Trump administration defense contract, triggering a dramatic 318% rally in a micro-cap stock on speculative drone defense demand.

The headline indicates Quantum Cyber (ticker QUCY) executed an IP license agreement with BP United Inc. for autonomous drone platform technology, explicitly connected to Trump administration funding for drone warfare reaching $55 billion. This is a classic micro-cap catalyst: a small company securing rights to defense technology during a period of elevated government spending signals potential revenue upside and military contracts. However, the headline is truncated and lacks detail on exclusivity scope, revenue terms, or timeline to commercialization. The stock's extreme move suggests market enthusiasm for the drone defense narrative rather than clarity on financial impact. Without the full press release text, we cannot verify the exclusivity claims, contract value, or likelihood of actual government procurement. The 318% jump is consistent with small-cap momentum trading on headline-driven defense sector enthusiasm, amplified by the stock's likely low float and illiquidity.

AIIO

Robo.ai Inc.Consumer Cyclical

$2.61+$1.33

+103.9%

NASDAQ · Mkt cap $487 M

Robo.ai announced the appointment of a new CTO at its recently acquired Neurovia AI subsidiary, signaling progress on the acquisition integration and potentially boosting investor confidence in the AI data processing business.

On May 13, Robo.ai announced that Mansoor Ali Khan, an Abu Dhabi-based tech executive, has been appointed Chief Technology Officer of Neurovia AI, the company Robo.ai recently acquired. This leadership appointment represents concrete progress on integrating what appears to be a strategically important AI and data processing acquisition. For a small-cap stock trading at $2.61 with a $25 million market cap, such announcements can generate outsized enthusiasm, especially if investors view the appointment as validating the acquisition thesis or signaling accelerated execution. The 103.91% gain (to $2.61) exceeds the 65.2% intraday gain reported earlier in the day, suggesting momentum built through the session as the news circulated. However, the headlines do not provide detail on Khan's track record, the scope of Neurovia's operations, or guidance on expected synergies, limiting assessment of whether the move represents substantive value creation or primarily represents sentiment improvement in a thinly traded micro-cap.

AEHL

Antelope Enterprise Holdings LimitedIndustrials

$3.62+$1.51

+71.6%

NASDAQ · Mkt cap $6.5 M

No news headlines were found in the last 48 hours, so the 71.56% gain likely stems from technical factors, delayed news pickup, or retail interest in a low-priced stock, but the specific catalyst cannot be identified from available information.

Despite the significant +71.56% rally placing AEHL as the fourth biggest gainer on 2026-05-13, no news headlines appeared in the Yahoo Finance RSS feed over the preceding 48 hours. This disconnect suggests several possibilities. First, the move may reflect delayed market reaction to news released earlier and not yet indexed by the RSS source. Second, it could be driven by technical factors such as short covering, options expiration effects, or algorithmic trading in a low-priced, potentially lower-liquidity name. Third, for a stock trading at $3.62, retail enthusiasm or social media discussion may drive moves without corresponding press releases. Fourth, there may be company-specific news released through channels outside the RSS feed monitored. Without access to SEC filings, earnings announcements, merger activity, or other official disclosures from the snapshot date, pinpointing the specific catalyst is not possible from the evidence provided.

YMAT

J-Star Holding Co., Ltd. Ordinary SharesBasic Materials

$0.85+$0.34

+66.2%

NASDAQ · Mkt cap $7.3 M

No news directly explaining YMAT's 66% gain was provided; the move likely reflects either a short squeeze, technical rebound from an extremely depressed price, or an undisclosed catalyst not captured in the headlines reviewed.

The headline provided only lists other gainers in the consumer discretionary sector on the same day but contains no information about YMAT itself. YMAT trades at $0.85, suggesting either a highly distressed or penny-stock status, which makes the stock susceptible to outsized percentage moves on modest absolute dollar volume. Extremely low-priced stocks often experience sharp rallies driven by technical factors such as short covering or oversold bounces, retail trading attention, or news that hasn't yet been indexed in major financial RSS feeds. Without a specific catalyst named in the available headlines, we cannot isolate the cause, only note that this price tier and volatility pattern are consistent with either technical trading activity or a company-specific event that simply wasn't included in the news sample provided.

FCHL

Fitness Champs Holdings Limited Common StockConsumer Defensive

$2.03+$0.70

+52.6%

NASDAQ · Mkt cap $1.5 M

FCHL surged 52.63% on May 13 following a sharp after-hours jump on May 12 that coincided with pump-and-dump fraud allegations, though the headlines do not establish why the stock continued rising during regular trading despite those negative reports.

The evidence shows FCHL jumped 44% in after-hours trading on May 12 amid pump-and-dump fraud allegations, then gained another 53% during May 13 regular trading. The headlines explicitly mention the fraud allegations but do not explain the continued rally on May 13. One headline notes FCHL was already one of the worst performers in 2026 prior to this move, and the company had priced a best-efforts public offering around April 17 expected to raise ~$5 million. The disconnect between negative fraud allegations and strong gains suggests either retail momentum, short-covering, or technical factors like squeeze dynamics in a very small-cap stock (market cap $1.6 million). However, no news headline provides a specific catalyst that would justify the May 13 continuation of gains.

VELO

Velo3D, Inc.Technology

$21.01+$6.95

+49.4%

MEI

Methode Electronics, Inc.Technology

$13.87+$4.51

+48.2%

NYSE · Mkt cap $546 M

MEI jumped 48% on May 13, 2026, but the only available headline is a generic market-mover article that mentions a 34% intraday gain without disclosing any company-specific news or catalyst.

The provided news content is a boilerplate stock movement summary that reports MEI's 34% intraday rise but offers no explanation for the move itself. No earnings report, guidance change, contract award, financing event, product announcement, or other corporate action is mentioned in the available headlines. For a stock of this size and sector, large single-day moves of this magnitude typically stem from earnings surprises (positive or negative), material contract wins in automotive or industrial electronics, M&A news, capital restructuring, short-squeeze pressure, or significant management changes. Without access to company-specific announcements or SEC filings issued on May 13 or the preceding day, we cannot confirm which of these categories applies here. The 48% move shown in the snapshot exceeds even the 34% intraday figure quoted, suggesting either late-day strength or a data timing difference.

BESS

Bimergen Energy CorporationUtilities

$3.47+$1.00

+40.5%

AMEX · Mkt cap $26 M

Bimergen Energy jumped 40.5% on news of a $2 billion asset growth plan to be presented May 18th at the LD Micro conference, signaling significant strategic expansion in battery storage.

On May 12, Bimergen announced it will present a $2 billion asset growth plan at the LD Micro 16th Annual Invitational conference scheduled for May 18. This forward-looking announcement appears to have driven investor enthusiasm ahead of the actual presentation, typical of micro-cap and small-cap energy stocks that respond strongly to growth narratives. The company operates utility-scale and distributed battery energy storage systems, a sector benefiting from energy transition tailwinds. The 40.49% single-day move reflects both the magnitude of the announced growth ambition and the speculative nature of trading in securities of this market capitalization. No earnings surprise or operational update was provided in the available headlines to anchor fundamentals to the move.

RVI

Robinhood Ventures Fund IFinancial Services

$73.71+$20.22

+37.8%

NYSE · Mkt cap $749 M

A Yahoo Finance article published on 2026-05-12 discussing Robinhood's expansion into private markets via Ventures Fund II likely drove the +37.80% jump, as the news highlights new revenue opportunities and retail access to early-stage startups.

The headline explicitly connects Robinhood's Ventures Fund II launch to potential growth in HOOD's business model by diversifying beyond trading into private market investing. The article frames this as a strategic move to offer retail investors access to early-stage startups while generating new revenue streams for the parent company. For a venture fund vehicle like RVI, this news would be directly relevant as it signals expanded opportunity and institutional confidence in the venture strategy. The timing of the 37.80% gain on the day following the article publication suggests the market reacted positively to the growth narrative. However, we lack details on fund size, specific investments announced, or any earnings/guidance updates that might have independently driven the move.

FRVO

Fervo Energy Co.Utilities

$36.54+$9.54

+35.3%

VIVO

VivoPower PLCEnergy

$4.23+$1.10

+35.1%

NASDAQ · Mkt cap $65 M

No news headlines were available in the last 48 hours to explain VIVO's 35% gain on May 13, 2026, so the catalyst remains unclear from public sources.

The absence of recent news headlines makes it impossible to identify a specific catalyst for VIVO's strong 35% single-day rally. VivoPower is a renewable energy and electric vehicle charging infrastructure company, and stocks in this sector can move sharply on several categories of events: announced contracts or partnerships, financing updates, operational milestones, changes in energy policy or subsidy landscapes, short-covering activity, or technical momentum. Without access to news from the specific date or intraday developments, any explanation would be speculation. The stock's rank as the 12th biggest gainer suggests broad market interest that day, but this alone does not indicate whether the move was driven by company-specific fundamentals, sector rotation, or technical factors.

VVPR

VivoPower International PLCTechnology

$4.22+$1.09

+34.8%

NASDAQ · Mkt cap $82 M

No news headlines were found in the last 48 hours to explain VVPR's 34.82% surge, so the catalyst remains unclear from publicly available sources.

The absence of any recent news in the provided headline feed makes it impossible to attribute this sharp gain to a specific announced event like earnings, contract awards, regulatory approvals, or guidance changes. A 35% single-day move in a micro-cap stock like VVPR could stem from several categories of catalyst: delayed or embargoed news not yet indexed by Yahoo Finance, a technical or sentiment shift driven by social media or retail attention, short covering if the stock has notable short interest, execution of a previously announced corporate action, or announcement on the company's own investor relations channels ahead of wire service pickup. Without access to real-time news from the company or granular volume and short-squeeze data, attributing the move remains speculative.

HYLN

Hyliion Holdings Corp.Consumer Cyclical

$3.59+$0.91

+33.7%

FNGR

FingerMotion, Inc.Communication Services

$1.07+$0.26

+32.1%

NASDAQ · Mkt cap $14 M

No news headlines were found in the last 48 hours, so the 32% gain is unexplained by reported corporate events. The jump likely reflects technical trading, retail interest, or an unreported announcement.

FingerMotion is a micro-cap stock trading at $1.07 with no recent news coverage available through Yahoo Finance RSS. A 32% single-day gain on a stock of this size and price point is not uncommon and can be driven by several non-news factors: technical bounces off support levels, short-squeeze activity if the stock has high short interest, retail trading interest on social media, options-related gamma effects, or delayed or unannounced corporate developments not yet captured in major news feeds. Micro-cap stocks are also subject to lower liquidity, meaning smaller absolute volume shifts can produce outsized percentage moves. Without headline evidence, we cannot attribute this move to earnings, guidance, partnerships, regulatory action, or other fundamental catalysts.

FEAM

5E Advanced Materials Inc.Basic Materials

$1.99+$0.48

+31.8%

NASDAQ · Mkt cap $66 M

5E Advanced Materials announced its first boric acid offtake agreement and reported Q3 2026 commercial milestones on May 12-13, triggering the 31.79% surge as investors rewarded the company's progress on product commercialization and customer contracts.

The company reported several concrete operational achievements during its fiscal Q3 2026 earnings window, most notably signing its first milestone offtake heads of agreement with a domestic industrial customer for boric acid products. Additional announcements highlighted advancement in specialty product development (meta boric acid and ferroboron) and ongoing financing efforts. These represent tangible validation of the company's business model moving from development into commercial deployment. For a small-cap advanced materials company historically challenged by geopolitical headwinds and capital constraints, the execution of an actual offtake agreement—a binding commitment from a customer—signals reduced execution risk and near-term revenue visibility. This type of concrete customer win typically drives outsized percentage moves in microcap equities where sentiment shifts rapidly based on proof points of commercial traction.

NBIG

Leverage Shares 2x Long NBIS Daily ETF

$25.79+$6.17

+31.4%

NASDAQ

No news headlines were found in the last 48 hours, but NBIG is a 2x leveraged long ETF tracking NBIS, so a sharp gain likely reflects a strong rally in the underlying index amplified by the fund's leverage structure.

NBIG is a leveraged ETF product designed to deliver twice the daily return of its underlying index NBIS. With no news headlines available to explain the move, the most probable explanation is that the underlying NBIS index gained substantially on May 13, 2026, and the 2x leverage multiplied that gain. A roughly 15-16% move in NBIS would produce a 31% move in NBIG when leverage is factored in. Without access to NBIS price action or broader market data for that date, we cannot confirm the specific driver, but leveraged ETFs are inherently sensitive to their underlying constituents' performance. The move could reflect broad market strength, sector rotation, or a specific event affecting NBIS holdings, but without news or data on the underlying index, this remains inference rather than confirmed fact.

PMAX

Powell Max Limited Class A Ordinary SharesFinancial Services

$3.41+$0.81

+31.2%

NASDAQ · Mkt cap $2.1 M

No news headlines were available in the last 48 hours for PMAX, so the 31% gain on May 13, 2026 cannot be attributed to a specific disclosed catalyst. The move likely reflects either technical/momentum trading, a delayed or unindexed announcement, or market speculation.

The absence of any recent news coverage is noteworthy given the magnitude of the move, ranking PMAX as the 18th biggest gainer of the day. This suggests the catalyst was either not captured by the Yahoo Finance RSS feed, emerged from a non-traditional source, or was not formally announced. For a small-cap equity like Powell Max Limited, possible explanations include technical rebounds after oversold conditions, short covering if the stock has significant short interest, an earnings release or guidance update not yet indexed by major news aggregators, insider buying disclosure, or speculative positioning ahead of an expected event. Without verifiable headlines tied to a specific corporate action or market event, attributing the move requires inference rather than fact.

NBIL

GraniteShares 2x Long NBIS Daily ETF

$36.78+$8.71

+31.0%

NASDAQ

No news was published in the last 48 hours, but NBIL is a 2x leveraged ETF tracking NBIS, so a roughly 15% gain in the underlying would mechanically produce this 31% move.

Yahoo Finance returned no headlines for the snapshot date or preceding 48 hours, so we cannot point to a specific catalyst. However, NBIL's structure as a 2x long daily ETF explains the outsized move without additional news. The fund uses leverage to amplify daily returns of its underlying index or security. A 15% move in NBIS would mechanically deliver approximately a 31% move in NBIL, accounting for compounding and daily rebalancing effects. The lack of news does not mean there was no catalyst for NBIS itself; the underlying could have reacted to sector rotation, positive sentiment, technical breakout, or company-specific developments not yet appearing in the Yahoo RSS feed. Without visibility into NBIS news, the source of the underlying gain remains opaque, but the leveraged structure fully explains NBIL's amplified response.

REPL

Replimune Group, Inc.Healthcare

$5.30+$1.21

+29.6%

GUTS

Fractyl Health, Inc. Common StockHealthcare

$0.95+$0.21

+29.2%

NASDAQ · Mkt cap $114 M

Fractyl Health reported Q1 2026 earnings and highlighted pivotal clinical trial progress for its Revita therapy, including upcoming data readouts in Q2-Q4 2026, driving a 29% rally on positive clinical and financial outlook despite the stock's historically depressed price.

On May 13, Fractyl Health released its Q1 2026 earnings results and held a conference call that emphasized several near-term catalysts: 1-year data from the REVEAL-1 Cohort expected in Q2 2026, 1-year randomized data from REMAIN-1 Midpoint Cohort in Q3 2026, and pivotal topline 6-month randomized data in early Q4 2026. Management stated the company remains on track for these milestones and highlighted clinical, regulatory, and reimbursement developments during the call. The headlines indicate "significant advancements in clinical trials and a robust financial outlook," suggesting the earnings beat or positive guidance drove investor enthusiasm. For a micro-cap biotech stock trading at $0.95, positive clinical progress toward pivotal data approval is a high-impact catalyst. The timing of the earnings release and call on May 13 directly aligns with the intraday price surge.

DXF

Eason Technology LimitedFinancial Services

$0.76+$0.17

+29.1%

AMEX · Mkt cap $1.6 M

DXF jumped 29% on a company statement addressing unusual market action on May 12th, though the full details of that statement were not disclosed in available headlines, leaving the specific catalyst unclear.

The company issued a formal statement on May 12 regarding unusual market action, which temporally aligns with the 29% gain observed on May 13. However, the headlines provided only announce that a statement was issued without disclosing its contents. The statement could have addressed positive developments, clarifications on prior concerns, or explanations that restored investor confidence. Additionally, a separate headline noted that Asian equities traded as ADRs fell sharply on Tuesday, suggesting sector-wide pressure. The timing of DXF's statement and subsequent recovery suggests management action may have countered negative sentiment, but without access to the statement's full text, the specific reason for the rebound remains inference rather than established fact. For a micro-cap trading at $0.76, moves of this magnitude can also reflect low liquidity and technical factors.

MOVE

Corvex, Inc.Technology

$19.25+$4.16

+27.6%

NOTV

Inotiv, Inc.Healthcare

$0.31+$0.07

+27.2%

NASDAQ · Mkt cap $387 K

No news headlines were found in the last 48 hours, so the 27% gain on NOTV likely reflects either a technical or sentiment-driven bounce, short covering, or a delayed market reaction to an earlier announcement not captured in the RSS feed.

Despite a strong single-day gain of over 27%, no recent news headlines from Yahoo Finance RSS were available to identify a specific catalyst. This creates a gap between the price action and documented information. For a micro-cap stock trading at $0.31, common drivers of sharp single-day moves without corresponding press coverage include technical bounces off support levels, short squeeze activity given potential high short interest at very low price points, delayed market reactions to earlier announcements that did not resurface in RSS feeds, or shifts in retail attention. Without access to the company's recent filings, insider activity, or broader market sentiment data, attributing the move to a particular cause would be speculative.

Jianzhi Education Technology Group Company LimitedTechnology

$0.93+$0.20

+27.2%

NASDAQ · Mkt cap $4.1 M

No specific news about JZ was provided; the 27% gain occurred on a day of broad strength in low-priced stocks, suggesting the move may reflect technical trading, short covering, or general market momentum rather than company-specific catalysts.

The only headline provided is a generic market roundup mentioning other consumer discretionary gainers (Robo.ai up 65%, Fitness Champs up 53%) with no mention of JZ itself. This suggests JZ's move was not driven by breaking news from the company. For a sub-$1 micro-cap educational technology stock, moves of this magnitude are common during periods of broad retail interest or short-squeeze activity in the low-priced equity space. Without company-specific news, the most likely explanations are technical bounce-backs, short covering, index inclusion rumors, or momentum trading from retail investors seeking outsized percentage gains. Educational tech stocks can also respond to broader sector sentiment shifts, but no such catalyst appears in the provided headlines.

KULR

KULR Technology Group, Inc.Technology

$4.05+$0.86

+27.0%

OCG

Oriental Culture Holding Ltd.Consumer Cyclical

$2.36+$0.50

+26.9%

NASDAQ · Mkt cap $3.4 M

No company-specific news was provided for OCG. The 26.88% gain on a day when the broader market was mixed suggests either a delayed earnings or regulatory announcement, a short squeeze, or sector-specific momentum in small-cap stocks.

The single headline provided concerns broad U.S. macro data (producer prices, Dow and NASDAQ moves) and contains no information about Oriental Culture Holding Ltd. or its business. OCG is a micro-cap stock trading on NASDAQ, and such securities often exhibit high volatility independent of broader market conditions. The gain occurred on a day when large-cap indices were mixed, which actually argues against macro factors as the primary driver. Possible explanations include a company announcement not yet captured in the news feed, short-covering or technical bounce following prior weakness, or sector-specific news affecting Chinese cultural or holding companies. Without access to OCG's own earnings, guidance, regulatory filings, or partnership announcements, the specific catalyst remains unknown.

GWH

ESS Tech, Inc.Industrials

$0.98+$0.21

+26.7%

NYSE · Mkt cap $23 M

GWH gained 26.7% but no specific news headline directly tied to ESS Tech was provided; the only article snippet references other industrial stocks and appears truncated, leaving the catalyst unclear.

The provided headline is a generic market-mover roundup mentioning Velo3D earnings and other industrials, but does not contain substantive information about GWH or ESS Tech itself. The snippet appears incomplete and does not explain GWH's jump. Without confirmed news, the move could reflect several possibilities common to small-cap industrial or energy-storage plays: positive sector rotation, short covering, technical momentum off a low base (the stock trades at $0.98, making percentage moves volatile), delayed positive news from an earlier earnings or earnings-adjacent announcement, or retail trading activity. Energy-storage companies in particular have been subject to significant sentiment swings based on policy signals and funding cycles, but none of that is documented in the provided headlines.

OUST

Ouster, Inc.Technology

$34.17+$7.07

+26.1%

NASDAQ · Mkt cap $2.6 B

Ouster announced qualification of its REV8 Native Color Lidar sensors for the NVIDIA DRIVE Hyperion autonomous vehicle platform on May 12, which likely drove the 26% single-day rally as a major partnership validation for its core AV sensor business.

On May 12, Ouster announced that its new REV8 OS family of digital lidar sensors received qualification to run on NVIDIA's DRIVE Hyperion platform, a critical infrastructure for autonomous vehicle development. This is a tangible product milestone that signals commercial traction in the high-stakes autonomous driving sensor market. The prior day's article titled "What Do You See If You Look Beyond Ouster Inc (OUST)'s Q1 Loss?" suggests the stock had been climbing despite losses, indicating investor focus on growth and strategic partnerships rather than near-term profitability. The NVIDIA partnership announcement provides concrete validation that institutional AV developers will adopt Ouster's sensors, reducing execution risk. The timing of the gain on May 13 aligns directly with the May 12 morning press release, making this the most probable catalyst rather than broader market moves or unrelated news.

ZONE

CleanCore Solutions, Inc.Industrials

$0.58+$0.12

+25.9%

WHWK

Whitehawk Therapeutics IncHealthcare

$4.93+$1.01

+25.8%

NASDAQ · Mkt cap $254 M

Whitehawk Therapeutics announced an $87.5 million private placement equity financing on May 13, which likely drove the 25.77% intraday gain as investors reacted positively to the capital raise.

The company disclosed a significant private placement equity financing of $87.5 million on the morning of May 13, 2026. For a clinical-stage oncology therapeutics company, a capital raise of this magnitude is a material corporate event that typically signals strong investor confidence and provides runway for advancement of the company's pipeline. The timing aligns precisely with the stock's upward move during both pre-market and intraday trading on the same day. The news headlines confirm WHWK moved upward during the session but do not provide additional details on the terms, use of proceeds, or market reception beyond the fact of the announcement itself. Private placements at clinical-stage biotech companies often attract specialized investors and can be viewed favorably if the valuation is reasonable relative to the company's stage and assets.

SRXH

SRx Health Solutions Inc.Technology

$0.15+$0.03

+25.8%

INBS

Intelligent Bio Solutions Inc.Healthcare

$3.99+$0.81

+25.5%

NASDAQ · Mkt cap $8.1 M

Intelligent Bio Solutions reported 46% year-over-year revenue growth in Q3 with cartridge revenue surging 59%, driving strong demand in its razor-razorblade model, likely triggering the 25% stock jump.

The company disclosed fiscal third quarter results showing accelerating top-line growth and a favorable product mix shift. Cartridge sales, which generate recurring revenue, jumped 59% year-over-year and now represent 66% of quarterly sales, indicating successful execution of its consumables-focused business model. Nine-month revenue of $3.07 million reflects 39% year-over-year growth, positioning the firm well relative to its size and stage. For a small-cap biotech or diagnostics company, sustained double-digit growth with improving unit economics in the high-margin consumables segment typically justifies significant near-term revaluation. The timing of the earnings release directly aligns with the stock's 25% gain on May 13, establishing a clear causal link.

ELMD

Electromed, Inc.Healthcare

$34.03+$6.83

+25.1%

AMEX · Mkt cap $341 M

Electromed reported its Q3 2026 earnings with record revenue, 14 consecutive quarters of growth, and an earnings surprise of +34.62%, triggering the 25% rally as investors repriced the stock upward on the strong beat and guidance signals.

The three headlines from May 12-13 all address the same catalyst: Electromed's Q3 2026 earnings announcement. The company delivered both earnings and revenue surprises, with earnings beating estimates by 34.62% and revenue beating by 4.35%. The press releases emphasize record financial performance, 14 consecutive quarters of growth, strategic campaigns, and sales force expansion. While the revenue beat margin is modest at 4.35%, the earnings beat of 34.62% is substantial and indicates margin expansion or operational efficiency improvements. The timing of the move—announcement on May 12 evening, stock jump on May 13 open—aligns with standard post-earnings reaction. No forward guidance changes, M&A announcements, or material risks are mentioned in the headlines, so the move appears driven purely by the magnitude of the earnings surprise and the positive narrative around consecutive growth and strategic execution.

SLS

SELLAS Life Sciences Group, Inc.Healthcare

$6.53+$1.31

+25.1%

NASDAQ · Mkt cap $2.8 B

SELLAS Life Sciences reported Q1 2026 results on May 13 and announced that its pivotal Phase 3 REGAL trial for AML treatment has reached 78 events as of May 11, positioning the company near a critical trial readout, likely driving the 25% surge.

The headlines establish that SELLAS reported first-quarter 2026 financial results and provided a corporate update on May 13, the same day as the stock's 25% jump. The key catalyst appears to be news that the Contract Research Organization informed the company that 78 events have occurred in the pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) for acute myeloid leukemia as of May 11. The headlines characterize the company as nearing a pivotal trial readout with the leukemia pipeline progressing. For a clinical-stage or late-stage biotech company, approaching a major trial readout without negative interim signals is typically viewed as de-risking, and the disclosure of event accumulation toward completion of the trial suggests the readout may be imminent. This is a reasonable catalyst for a significant single-day gain in a micro-cap healthcare stock, where trial progression news carries outsized weight.

VNET

VNET Group, Inc.Technology

$11.28+$2.26

+25.1%

NASDAQ · Mkt cap $1.9 B

VNET surged 25% on announcement of new strategic investors PJ Millennium I Limited and PJ Millennium entering the company, signaling confidence in the Chinese data center operator's business prospects.

On May 13, VNET announced that PJ Millennium I Limited and PJ Millennium have become strategic investors in the company. This news directly preceded the 25% stock jump, making it the clear catalyst for the day's move. Strategic investor entry typically signals external validation of a company's market position and growth prospects, particularly relevant for VNET as a leading carrier- and cloud-neutral internet data center provider in China. The announcement arrived during a period of broader strength in Asian equities traded as ADRs, which may have provided tailwind. The company is scheduled to report Q1 2026 results on May 26, creating potential near-term catalysts ahead.

PLUT

Plutus Financial Group LimitedFinancial Services

$2.75+$0.55

+25.0%

NASDAQ · Mkt cap $42 M

No news was found in the last 48 hours to explain PLUT's 25% gain, so the driver remains unclear; the jump may reflect delayed reporting of an announcement, technical factors, or sector momentum.

Yahoo Finance returned no headlines for Plutus Financial Group in the past 48 hours despite a substantial 25% intraday gain ranking it among the day's top movers. This absence of news coverage does not rule out a real catalyst—it may reflect timing lag in news aggregation, a very recent after-hours development, or a corporate action not yet widely reported. Alternatively, the move could stem from technical factors such as short covering, options expiration dynamics, or sentiment shifts in fintech or financial services sectors. Without access to company filings, SEC announcements, or broader market context for the date in question, we cannot identify the specific trigger. Investors should verify whether an earnings release, guidance change, partnership, or regulatory action occurred independently of the news feed shown here.

AMZE

Amaze Holdings, Inc.Technology

$0.19+$0.04

+24.9%

AMEX · Mkt cap $1.5 M

No news headlines were found in the last 48 hours, so the 24.89% gain on this micro-cap penny stock likely reflects technical trading activity, short covering, or an undetected announcement not yet indexed by Yahoo Finance.

AMZE is a very low-priced security trading at $0.19, which typically exhibits high volatility and can be sensitive to minimal trading volume shifts, short squeezes, or retail sentiment changes. The absence of any reported headlines in the search window means we cannot tie this move to a specific corporate event like earnings, product news, financing, or guidance. For stocks in this price range, upward moves of this magnitude are often driven by technical factors such as moving-average breakouts, low-float short covering, or retail trading momentum rather than fundamental catalysts. It is also possible that a material announcement was made but has not yet propagated to the news feed being queried, or that the move is driven by market-wide or sector-specific sentiment not tied to company-specific news.

FAMI

Farmmi, Inc.Consumer Defensive

$1.46+$0.29

+24.8%

NASDAQ · Mkt cap $3.9 M

No news headlines were available in the last 48 hours for FAMI, so the 24.79% gain cannot be directly attributed to a disclosed corporate event or market announcement.

With no recent headlines to explain the move, the jump in FAMI stock likely stems from one of several common catalysts for micro-cap stocks. Technical factors such as short covering, low liquidity amplifying small buy orders, or momentum trading on the NASDAQ can drive outsized percentage gains on minimal volume. Alternatively, the move may reflect delayed market reaction to an older announcement not captured in the 48-hour news window, or trading based on unconfirmed rumors or social media discussion. FAMI's position as a small-cap agricultural food company means it receives sparse analyst coverage and media attention, making such moves harder to trace. Without access to intraday trading data, SEC filings from the past week, or broader market context, identifying the specific catalyst remains speculative.

LKSPR

Lake Superior Acquisition Corp. – Rights

$1.00+$0.20

+24.5%

NASDAQ

No news headlines were found in the last 48 hours, so the 24.54% gain in LKSPR rights cannot be attributed to a documented catalyst. The move is likely driven by technical factors, a delayed market reaction, or developments not yet captured in headline feeds.

Lake Superior Acquisition Corp. rights (LKSPR) traded up sharply on May 13, 2026, with no corresponding news in the Yahoo Finance RSS feed covering the prior 48 hours. This absence of headline catalyst makes it difficult to pinpoint a specific driver. However, SPAC-related securities, including rights offerings, can be volatile and are sometimes subject to technical rebounds, short-covering, or end-of-week positioning shifts. Rights specifically have asymmetric payoff structures and thinner trading, which can amplify small volume shifts into larger percentage moves. A delayed earnings report, a regulatory filing, a merger timeline update, or commentary from management could have circulated through other channels not captured in the RSS feed. Without access to those data points, the true cause remains speculative.

HUMA

Humacyte, Inc.Healthcare

$1.13+$0.22

+24.2%

NASDAQ · Mkt cap $157 M

Humacyte reported Q1 2026 earnings with Symvess sales of $0.5 million (up from $0.1 million in Q1 2025) plus strategic leadership appointments (new Chief Commercial Officer and Chief Surgical Officer), likely driving the 24% gain despite missing overall revenue estimates.

Humacyte released first-quarter 2026 financial results on May 13, 2026, showing mixed signals. On the negative side, the company missed revenue estimates by 59.76%. However, the narrative appears constructively framed around Symvess bioengineered vascular product momentum: sales quintupled year-over-year to $0.5 million, and management announced two senior appointments (Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer) positioned to accelerate adoption and bring clinical credibility. The earnings beat on earnings per share by 10% also likely helped sentiment. For a pre-revenue-stage biotech stock, a 5x sales increase and credentialed leadership hires can signal inflection points, which may have outweighed the absolute revenue miss in investor perception. The stock's low absolute price ($1.13) also suggests high volatility and retail interest, amplifying percentage moves.

MXCT

MaxCyte, Inc.Healthcare

$1.02+$0.20

+24.1%

NASDAQ · Mkt cap $136 M

MaxCyte reported Q1 earnings that beat revenue expectations by 31% and earnings by 58% on May 12, alongside reiterated full-year guidance of $30-32 million, driving the 24% intraday rally.

MaxCyte released Q1 2026 results showing $9.7 million in total revenue (with $6.2 million core revenue) that exceeded analyst consensus. The earnings surprise of +57.90% and revenue surprise of +31.31% are concrete positives. However, the underlying picture is mixed: management noted that discontinued SPL programs and inventory management by the largest customer weighed on core revenue growth. The company reiterated its full-year guidance at $30-32 million, suggesting confidence despite near-term headwinds. One investor note from Minot Light Capital referenced MXCT as a "high-conviction bet," which may have amplified positive sentiment. The gain appears driven primarily by the earnings beat relative to depressed expectations, though the stock remains deeply underwater at $1.02, suggesting investors are betting on improved execution or a potential turnaround rather than near-term stability.

MTVA

MetaVia Inc.Healthcare

$1.20+$0.23

+23.7%

NASDAQ · Mkt cap $7.6 M

No news headlines were found in the last 48 hours, so the 23.71% jump is unexplained by publicly reported events. The move likely reflects technical trading, delayed news propagation, or unconfirmed rumors in a low-priced stock.

MetaVia Inc. experienced a sharp single-day gain of nearly 24% with zero supporting headlines in the most recent news feeds. For a micro-cap stock trading at $1.20, such moves are not uncommon and can be driven by several non-news factors: technical breakouts above resistance levels, short-covering rallies, options expiration effects, or retail trading momentum. Alternatively, a material announcement (earnings, partnership, or corporate action) may have occurred but not yet propagated to major news aggregators, or the catalyst may exist only in social media or trading forums without formal press release confirmation. Without headline evidence or structural knowledge of MTVA's capital structure or float characteristics, attributing this move to any specific cause remains speculative.

HLP

Hongli Group Inc.Basic Materials

$1.16+$0.22

+23.4%

NASDAQ · Mkt cap $90 M

Hongli Group reported strong fiscal 2025 results with 39% revenue growth to $19.6 million and a $3.8 million profit turnaround, likely driving the 23.4% single-day jump in the small-cap stock.

The company announced its full-year 2025 earnings on May 13, 2026, highlighting material operational improvements: revenue grew nearly 40 percent year-over-year and the firm swung from a loss position to a $3.8 million profit. For a micro-cap cold-rolled steel profile manufacturer trading under $1.20, this kind of profitability inflection and double-digit revenue acceleration represents a significant fundamental improvement. The timing of the announcement coinciding precisely with the trading date and the magnitude of the move (23.4%) are consistent with a positive earnings reaction. No contradictory headlines or offsetting news appear in the available feeds. The stock's rank as the 44th biggest gainer suggests broad market participation in the move, not isolated retail trading.

PLSM

Pulsenmore Ltd. Ordinary SharesHealthcare

$4.62+$0.87

+23.2%

NASDAQ · Mkt cap $20 M

No news headlines were published in the last 48 hours to explain PLSM's 23.20% gain. The jump likely reflects a delayed market reaction to a prior announcement, technical trading (short covering or oversold bounce), or an off-exchange development not yet picked up by major news feeds.

The absence of recent news headlines makes direct causation impossible to establish. PLSM gained over 23% on strong volume but without corresponding press coverage in the 48-hour window, several scenarios merit consideration. First, the stock may have reacted to news released earlier than 48 hours ago that is still driving momentum. Second, given that PLSM is a biomedical device company, catalyst categories that typically move such stocks include clinical trial results, regulatory approvals, partnership announcements, or earnings beats, though none appear in the available feeds. Third, the magnitude of the move (23%) suggests a meaningful event rather than pure technical trading, but without visibility into the catalyst, that remains inference. Technical factors such as short-squeeze activity or a bounce from an oversold condition are possible but speculative. The honest assessment is that the root cause is not evident from the information provided.

WGRX

Wellgistics Health, Inc.Healthcare

$0.10+$0.02

+23.1%

NASDAQ · Mkt cap $157 M

Wellgistics Health announced a pilot collaboration with Kare PharmTech targeting the $14 billion U.S. RPM and CCM services market, which likely drove the 23% gain as investors responded positively to a concrete partnership in a high-growth healthcare sector.

On May 13, 2026, Wellgistics Health released news of a Managed Service Organization (MSO) pilot collaboration with Kare PharmTech. The announcement highlighted the addressable market opportunity: the U.S. RPM (Remote Patient Monitoring) market alone is currently valued at $14 billion and is projected to grow to approximately $29 billion by 2030 at a 12.6% CAGR. For a micro-cap stock trading at $0.10, a concrete partnership announcement in a large and rapidly expanding market segment appears to have catalyzed investor interest. The timing of the news release (13:05 UTC on the same day as the price snapshot) aligns directly with the intraday move. The stock's low absolute price and ranking as the 46th biggest gainer suggest retail and speculative participation, which is consistent with a small-cap health-tech company announcing a growth opportunity.

BNCWZ

CEA Industries Inc.

$0.35+$0.07

+23.1%

NASDAQ

No news headlines were found in the last 48 hours for BNCWZ, so the 23% gain on May 13 cannot be attributed to a specific announced event. The move likely reflects technical buying, delayed news discovery, or market speculation.

The absence of recent news headlines for BNCWZ makes it impossible to identify a concrete catalyst for the +23.07% intraday move. Given that this is a micro-cap stock trading at $0.35, price swings of this magnitude can occur from several sources: technical chart breakouts or oversold bounces, retail attention through social media or message boards that may not appear in traditional news feeds, delayed market processing of older announcements, or simple low-liquidity volatility amplifying small order flows. Without access to real-time volume data, earnings surprises from prior days, or broker alerts, we cannot determine whether this was fundamentally driven or purely technical in nature.

CHGG

Chegg, Inc.Consumer Defensive

$1.14+$0.21

+22.9%

NYSE · Mkt cap $84 M

Chegg announced expansion into AI model training leveraging its proprietary learning data and subject matter expert network, signaling a strategic pivot to capitalize on AI demand and diversify revenue streams beyond its core tutoring business.

On May 13, 2026, Chegg announced a major strategic initiative to enter the AI model training market, positioning itself to monetize its decade of accumulated learning data, subject matter expertise, and network of educators. This announcement directly addresses investor concerns about the company's competitive positioning in an AI-driven education landscape and suggests management sees a high-margin revenue opportunity in providing training data and expertise to AI developers. The 22.88% intraday gain reflects market enthusiasm for this pivot, which transforms Chegg from a challenged tutoring platform into a potential AI infrastructure play. The timing and framing as "the next phase of strategic roadmap" suggests this is a calculated repositioning rather than a reactive move, which likely boosted credibility with growth-focused investors.

TSEM

Tower Semiconductor Ltd.Technology

$270.77+$49.94

+22.6%

NASDAQ · Mkt cap $27 B

Tower Semiconductor beat Q1 earnings expectations and issued strong Q2 guidance citing AI infrastructure demand, driving a 22.61% gain as the company reported nearly doubled operating profit and record revenue outlook.

Tower Semiconductor reported first-quarter 2026 results that exceeded Wall Street targets and accompanied them with upbeat second-quarter guidance, specifically attributing growth to AI infrastructure business momentum. Multiple headlines confirm the company posted sharp year-over-year profit increases and issued guidance for the highest quarterly revenue in company history. The silicon photonics market boom was cited as a tailwind. Additionally, a technical "Power Inflow" alert (a bullish order flow signal) was noted earlier in the trading session. The combination of a clear earnings beat, forward guidance raise, and thematic alignment with AI chip demand created multiple reinforcing catalysts for the stock's substantial 22.61% intraday jump.

LTRN

Lantern Pharma Inc.Healthcare

$2.51+$0.45

+21.8%

NASDAQ · Mkt cap $33 M

Lantern Pharma announced a $9.25 million registered direct offering on May 13, coinciding with the stock's 21.84% intraday jump, likely reflecting investor optimism about capital infusion ahead of Q1 earnings due May 15.

The registered direct offering announcement occurred on the same day as the stock's surge, making it the most plausible near-term catalyst. The offering targets existing shareholders and institutional investors, signaling confidence in the company's direction and providing runway for operations. The timing is notable because earnings are due just two days later on May 15, so the market may be interpreting the capital raise favorably as a signal of stability or upcoming positive results. Biotech microcaps often respond sharply to capital events, especially when paired with imminent earnings. However, without seeing the earnings report itself or details on the offering terms, the full picture of whether fundamentals support the move remains incomplete.

Biggest Losers

Wed, May 13, 2026 50

WOK

WORK Medical Technology Group Ltd.Healthcare

$2.76−$3.90

-58.6%

NASDAQ · Mkt cap $5.2 M

WOK stock surged 69.67% in after-hours trading on Tuesday following a disclosed strategic announcement by the Hangzhou-based medical device supplier, but reversed sharply during regular Wednesday trading, falling 58.56% and becoming the day's biggest loser, suggesting the initial reaction may hav…

The provided headlines confirm that WOK shares jumped 69.67% to $11.30 in after-hours trading on Tuesday following disclosure of an unspecified strategic announcement. However, the headline is truncated mid-sentence and does not reveal the substance of that announcement. The regular-session move on Wednesday—a 58.56% decline to $2.76—indicates either a sharp reversal of bullish sentiment, a correction of an oversold bounce, or release of details that negated the initial positive perception. Without the full text of the strategic disclosure or any follow-up reporting from Wednesday morning, the cause of the intraday reversal cannot be determined from the evidence provided. The extreme volatility and the truncation of the news summary make it impossible to confirm whether the Wednesday decline stemmed from disappointment with the announcement's details, short-covering reversal, or an entirely separate catalyst.

RVPH

Reviva Pharmaceuticals Holdings, Inc.Healthcare

$0.35−$0.44

-55.7%

NASDAQ · Mkt cap $6.6 M

RVPH plunged 55.73% on the day despite reporting Q1 2026 results and a positive patent filing for brilaroxazine, suggesting the market viewed the news as insufficient or disappointing relative to expectations, though the exact catalyst remains unclear from the available headlines.

The company released Q1 2026 financial results and announced a composition of matter provisional patent application for a new brilaroxazine formulation designed to extend exclusivity through 2046, along with updates on FDA feedback. These are typically viewed as positive developments in the biotech space, particularly a patent extension that could protect revenue streams. However, the headline snippet appears incomplete and cuts off mid-sentence regarding FDA feedback. The severity of the decline (55.73% placing it second among daily losers) suggests either the actual financial results missed badly, guidance disappointed, or there was negative FDA feedback or clinical data not captured in the provided headline fragment. Without access to the full earnings release or the complete FDA feedback detail, it is difficult to pinpoint the precise negative catalyst. The drop is disproportionate to typical intraday volatility and points to a material negative development, but the available evidence is incomplete.

BTM

Bitcoin Depot Inc.Financial Services

$2.62−$2.03

-43.7%

TLSI

TriSalus Life Sciences, Inc.Healthcare

$2.67−$1.89

-41.4%

NASDAQ · Mkt cap $338 M

TriSalus reported Q1 revenue that missed estimates by 15.25%, reduced full-year 2026 guidance due to commercial reorganization disruption, and faces FDA review delays, causing the sharp sell-off despite earnings beat and clinical progress.

The headlines establish that TriSalus delivered a significant revenue miss (down 15.25% versus estimates) for Q1 2026, which directly contradicts the positive clinical and commercial narrative. The company cited a broad commercial reorganization that disrupted near-term sales performance. Additionally, the earnings call highlighted FDA delays affecting a key pipeline program, which threatens future growth catalyst timing. While the company reported improved margins, robust clinical data, and published positive real-world outcomes in a peer-reviewed journal, these positives were overshadowed by the combination of missed revenue, reduced full-year guidance, and regulatory uncertainty. For a small-cap oncology biotech, revenue growth and pipeline advancement are critical valuation drivers; missing on current sales and pushing back approvals typically triggers sharp repricing regardless of clinical merit.

LGCB

Linkage Global Inc Ordinary SharesConsumer Cyclical

$0.33−$0.23

-40.3%

NASDAQ · Mkt cap $13 M

No news headlines were found in the last 48 hours, so the 40% drop cannot be attributed to reported events; the cause likely involves either a delayed announcement, technical selling, or a market-moving development not yet captured in major news feeds.

The absence of any news in the last 48 hours makes it difficult to pinpoint a specific catalyst for LGCB's sharp 40% decline. Penny stocks and micro-cap securities like Linkage Global are prone to sudden moves driven by several mechanisms: unannounced insider transactions, delayed regulatory filings, short-seller reports or social media claims that precede formal news coverage, technical breakdown below support levels triggering stop-loss selling, or delayed dissemination of material developments to mainstream financial news aggregators. Without documented headlines, the move falls into the category of unexplained daily volatility common in lower-liquidity securities, though the magnitude suggests something more than routine trading noise.

IDN

Intellicheck, Inc.Technology

$4.45−$2.77

-38.4%

NASDAQ · Mkt cap $62 M

Intellicheck reported record Q1 2026 results with higher revenue and profitability on May 12, but the 38% single-day plunge on May 13 suggests the market viewed the earnings as insufficient to justify valuation or forward guidance disappointed despite headline headline metrics.

The company announced record first-quarter revenue and improved profitability, with management citing growth in banking and lending segments that offset weakness in retail, automotive, and title verticals. By conventional metrics this appears positive. However, a 38% single-day collapse immediately following earnings typically indicates either (a) forward guidance or margin outlook disappointed materially relative to prior consensus, (b) management commentary on demand trends or competitive pressures spooked investors, or (c) the stock had priced in even stronger results. The headlines provided do not detail actual financial figures, guidance changes, or specific management commentary that would explain the severity of the selloff. Without access to the full earnings transcript analysis or analyst reaction, the precise trigger remains unclear, though post-earnings disappointment is the most probable category.

SBFM

Sunshine Biopharma, Inc.Healthcare

$0.66−$0.39

-37.1%

NASDAQ · Mkt cap $4.5 M

No news headlines were published in the last 48 hours about SBFM, so the 37% drop cannot be attributed to a named catalyst in the available record. The decline likely reflects a micro-cap biotech sell-off driven by sector rotation, profit-taking, or undisclosed company developments.

The absence of recent headlines is notable given the severity of the move, which ranks SBFM as the seventh-biggest loser on the day. For a micro-cap biotech stock trading near $0.66, price swings of this magnitude are not uncommon and often occur on thin volume. Without a published news event to anchor the analysis, the most probable causes fall into two categories: first, sector-wide or market-wide pressure that disproportionately affects small-cap biotech names; second, company-specific news that either was not yet picked up by Yahoo Finance RSS feeds, did not generate a formal headline, or occurred via SEC filing, press release, or social media without immediate broader distribution. Biotech stocks at this price point are also susceptible to technical liquidation and momentum reversals.

HTCO

High-Trend International GroupIndustrials

$7.25−$4.03

-35.7%

NASDAQ · Mkt cap $26 M

High-Trend International Group announced a $15 million registered direct offering priced at $7.25 per share on Wednesday, which typically dilutes existing shareholders and triggered the 35.73% premarket selloff.

The company priced a registered direct offering (RDO) of 2,307,700 Class A shares at $7.25 per share, raising $15 million from global institutional investors. RDOs are generally perceived negatively by markets because they represent immediate shareholder dilution and often signal that management believes the stock is overvalued or that the company faces near-term liquidity needs. The timing on May 13 coincides with premarket trading declines, indicating investors reacted to the offering announcement before regular trading opened. The prior news from May 11 about shareholder approval of corporate governance enhancements appears unrelated to the price drop. The magnitude of the decline (35.73%) is substantial but not unusual for stocks experiencing a large dilutive capital raise, particularly in smaller-cap stocks where relative share count increases are more pronounced.

YOOV

Concorde International Group Ltd.Industrials

$0.69−$0.33

-32.1%

NASDAQ · Mkt cap $139 M

A class action lawsuit notice from Bragar Eagel & Squire targeting Concorde investors likely triggered the sharp 32% sell-off, as such legal filings often signal material undisclosed losses or securities violations that the market is now pricing in.

The only substantive news in the past 48 hours is a law firm advertisement seeking lead plaintiffs in a class action against Concorde International Group Ltd., with a May 18 deadline to join. While the headline does not specify the underlying claim, such litigation notices typically follow disclosure of financial restatements, missed guidance, failed regulatory approvals, or executive misconduct. The timing and prominence of this notice being ranked among the day's top losers suggests the market is interpreting it as evidence of a material problem not yet fully priced in. However, the news item itself does not disclose what triggered the lawsuit or what investors actually lost, so the specific catalyst remains opaque. The stock's penny-stock price of $0.69 and extreme single-day loss are consistent with high-volatility micro-cap behavior and potential insolvency concerns.

BRCB

Black Rock Coffee Bar, Inc. Class A Common StockConsumer Cyclical

$7.65−$3.32

-30.3%

NASDAQ · Mkt cap $175 M

Black Rock Coffee Bar posted strong Q1 earnings with 23.7% revenue growth and opened nine new locations, but the market may have punished the stock on a miss in same-store sales growth of only 5.2% or concern over competitive pressures mentioned in the earnings call.

The company reported results on May 12 that included headline positives: robust 23.7% year-over-year revenue growth, opening of nine new stores in the quarter, and appointment of an experienced Chief Development Officer. However, the earnings call also highlighted same-store sales growth of 5.2%, which is a critical profitability metric that appears to have disappointed relative to expectations or prior trends. The headlines explicitly note the company is navigating challenges in same-store transactions and competitive pressures. A 30% single-day drop following earnings typically signals either a guidance cut, a margin miss, or a meaningful shortfall in organic sales growth. The 5.2% same-store sales figure, while positive, may have fallen well short of what investors anticipated, especially given the aggressive unit expansion strategy.

RCAX

Daily Target 2X Long RCAT ETF

$6.08−$2.57

-29.7%

NASDAQ

No news headlines were found in the last 48 hours, but RCAX is a 2X leveraged long ETF tracking RCAT, so a sharp decline in the underlying asset or broad market weakness would naturally amplify into a 29.71% drop in the fund itself.

The absence of any news headlines in the provided feed means we cannot point to a specific company announcement, earnings release, regulatory action, or market event as a direct cause. However, RCAX's structure as a daily target 2X leveraged long ETF is material context. Leveraged ETFs are designed to deliver two times the daily return of their underlying index or fund. This means a 15% decline in the RCAT underlying on the day would translate into approximately a 30% loss in RCAX, which aligns closely with the observed 29.71% drop. The most likely explanation is therefore a significant decline in RCAT itself, possibly driven by broad market weakness, sector rotation, or adverse news specific to RCAT that has not yet appeared in the Yahoo Finance headlines provided to us. Without access to intraday market data or news sources beyond the given feed, we cannot definitively identify the root cause.

REI

Ring Energy, Inc.Energy

$1.26−$0.52

-29.0%

AMEX · Mkt cap $357 M

Ring Energy announced a large equity offering (44.4 million shares priced on May 12) which typically causes shareholder dilution and downward pressure, compounded by a modest sector-wide energy decline.

The most direct catalyst is Ring Energy's public offering announcement on May 12, with pricing finalized on May 13. The company is issuing 44.4 million shares to raise $60 million. Equity offerings of this scale typically trigger selling pressure because existing shareholders face immediate dilution and the new supply often weighs on near-term price action. Additionally, the energy sector itself declined modestly on May 13, with the NYSE Energy Sector Index down 0.4% late in the day, providing a headwind. A 29 percent drop is severe relative to the sector decline alone, suggesting the offering announcement drove the majority of the sell-off. The timing (announcement on May 12, pricing on May 13, trading impact on May 13) aligns cleanly with shareholder capitulation following dilutive capital raise news.

UBXG

U-BX Technology Ltd.Communication Services

$0.15−$0.06

-28.8%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours, so the 28.77% drop cannot be attributed to a specific announced event; the move likely reflects technical selling, a delayed news announcement, or a sector-wide decline in this micro-cap stock.

The absence of any recent news headlines makes it impossible to identify a concrete catalyst for UBXG's sharp 28.77% decline. At a price of $0.15, this is a micro-cap security where price movements can be volatile and driven by factors other than company-specific news, such as broad market conditions, sector rotation, or technical selling pressure. Micro-cap stocks trading at penny or near-penny levels are also susceptible to liquidity events, short-covering squeezes, or delayed disclosure of material information that may not yet have propagated through major news feeds. Without access to SEC filings, company announcements, or breaking industry news within the past 48 hours, the specific reason for today's loss cannot be pinpointed from the provided sources.

REED

Reed's, Inc.Consumer Defensive

$1.79−$0.71

-28.4%

AMEX · Mkt cap $13 M

Reed's reported Q1 2026 earnings on May 12, triggering a 28.4% stock decline the following day, suggesting disappointing financial results or guidance drove the sharp selloff.

The timing and magnitude of the drop align directly with Reed's earnings release and conference call on May 12-13. The company announced Q1 2026 results and held a call to discuss them, with the transcript published the morning of the trading decline. While the headlines do not provide specific financial metrics, earnings misses, revenue declines, or negative forward guidance typically trigger sharp selloffs in consumer beverage stocks, particularly smaller-cap names trading near $1.79 with likely limited analyst coverage. The fact that this is the 14th biggest loser of the day on AMEX suggests sector-wide factors are not the driver; the move appears company-specific. Without access to the actual earnings numbers or call commentary, the most reasonable inference is that management communicated weaker-than-expected results or reduced forward guidance.

WIX

Wix.com Ltd.Technology

$55.32−$20.56

-27.1%

NASDAQ · Mkt cap $3.6 B

Wix.com reported Q1 earnings that missed profit expectations despite revenue meeting guidance, triggering a 27% sell-off as investors react to weaker-than-expected profitability and concerns about AI disruption in the web development market.

Multiple headlines from May 13 confirm that Wix reported first-quarter 2026 results with revenue largely in line with expectations but earnings significantly below analyst estimates. The company did announce accelerated investments in AI products including Wix Harmony and Base44, which executives called solid growth execution. However, the earnings miss appears to have overshadowed management commentary. Several outlets explicitly cited AI as a competitive threat to the business model. Notably, this sell-off occurred on a day when the broader Nasdaq and S&P 500 hit fresh highs and tech stocks were rallying, indicating the decline was company-specific rather than market-driven. Management reiterated full-year guidance, which failed to reassure investors concerned about margin pressure and competitive threats.

SOPA

Society Pass IncorporatedCommunication Services

$0.26−$0.10

-26.9%

NASDAQ · Mkt cap $7.7 K

SOPA dropped 26.86% with no news reported in the last 48 hours, making the precise cause unknowable from available evidence; the move is likely driven by technical selling, sector weakness, or an untracked announcement.

No headlines were found in the Yahoo Finance RSS feed for the last 48 hours surrounding this move, so the direct catalyst cannot be identified from news sources. Society Pass Incorporated is a micro-cap stock trading at $0.26, which makes it susceptible to several common drivers of sharp moves: technical selling into support levels or stop-losses, broader sector rotation or market weakness, delayed press releases not yet picked up by major financial news aggregators, short-covering or momentum liquidation, or low-volume capitulation. Without access to company filings, earnings releases, or confirmed announcements issued directly by the company in the relevant window, the specific reason for today's 26.86% decline remains inference rather than fact.

EMISR

Emmis Acquisition Corp. Rights

$0.10−$0.04

-26.5%

NASDAQ

No news headlines were available in the last 48 hours to explain the 26.51% decline in EMISR. The drop is likely due to typical SPAC rights-warrant volatility or general market sentiment toward blank-check vehicles.

Emmis Acquisition Corp. Rights (EMISR) traded down sharply with no supporting news in the recent news feed. This is a SPAC rights offering, a security type known for high volatility and sensitivity to shifts in investor appetite for blank-check structures. Rights offerings are particularly prone to decay in value as they approach or exceed their exercise deadline, especially if the underlying SPAC's deal status is uncertain or if broader sentiment toward SPACs has soured. Possible drivers include deterioration in deal negotiations, extension deadlines nearing, investor redemption activity, or simple rotation out of microcap SPAC-related securities. Without headlines confirming a specific event, the decline most likely reflects either technical selling pressure specific to rights expirations or a broader pullback in SPAC sentiment.

ATYR

aTyr Pharma, Inc.Healthcare

$0.40−$0.13

-25.3%

NASDAQ · Mkt cap $52 M

aTyr Pharma announced it must conduct a new Phase III trial of efzofitimod in sarcoidosis following FDA feedback, implying delays and uncertainty in a key program that likely disappointed investors expecting progress toward approval.

On May 11-12, aTyr disclosed that the FDA's Type C meeting feedback necessitated a redesign of its clinical strategy for efzofitimod in pulmonary sarcoidosis. Rather than advancing on the previously planned path, the company must now run a new Phase III trial, with an IND submission planned for June 2026. For a clinical-stage biotech with limited pipeline depth, a requirement to restart a late-stage trial signals extended timelines, increased costs, and reduced near-term probability of regulatory approval. The market typically penalizes such setbacks sharply. The May 13 announcement about investor conferences appears procedural and unlikely to be the negative catalyst. The 25% single-day drop aligns with the magnitude of disappointment a pivotal trial redesign would trigger in a stock trading near penny-stock levels where risk tolerance is already thin.

LMRI

Lumexa Imaging Holdings, Inc. Common StockHealthcare

$8.05−$2.45

-23.3%

NASDAQ · Mkt cap $1.1 B

Lumexa Imaging reported Q1 2026 earnings that management claimed were in line with expectations, but the 23% stock drop suggests investors were disappointed by either the actual results, forward guidance, or margins despite the earnings call framing the performance positively.

The company announced Q1 2026 results on May 12 alongside news of four new imaging center expansions, including a Pennsylvania joint venture with UPMC. Management characterized the quarter as meeting expectations with growth in advanced imaging modalities offsetting seasonal volume pressure and weather disruptions. However, the magnitude of the sell-off indicates a disconnect between management's narrative and investor reception. The drop could reflect weaker-than-expected margins despite revenue growth, disappointing guidance for future quarters, or concerns about execution risks on the expansion strategy. The lack of specific financial metrics in the headlines makes precise attribution difficult, but the timing directly correlates with earnings release and the earnings call occurring the morning of the price decline.

OPRX

OptimizeRx CorporationHealthcare

$4.92−$1.43

-22.5%

NASDAQ · Mkt cap $151 M

OptimizeRx beat Q1 earnings estimates and showed strong AI growth, but management cut full-year revenue guidance citing continued caution among life sciences customers, triggering the 22% sell-off as investors repriced expectations lower.

The earnings headlines present a classic miss-on-guidance scenario. OPRX delivered a massive earnings surprise (+1,300%) and beat revenue estimates by 7.59% for Q1, with Q1 revenue at $19.8 million and adjusted EBITDA of $3.3 million. However, management simultaneously lowered full-year 2026 revenue guidance to $95-$100 million, citing continued macroeconomic pressures and caution among life sciences customers. The company also launched a new DSP integration for EHR advertising, suggesting product momentum. In growth-stage software and healthcare IT stocks, forward guidance typically matters more than backward-looking earnings results. A lowered full-year outlook, even alongside strong near-term results, signals management's reduced confidence in demand trajectory and can trigger sharp repricing, especially if the guidance cut was unexpected or sharper than the market anticipated.

GILT

Gilat Satellite Networks Ltd.Technology

$15.65−$4.26

-21.4%

NASDAQ · Mkt cap $887 M

Gilat beat earnings estimates significantly but missed revenue expectations, and the stock has tripled in the past year, causing investors to take profits and demand more growth than the company delivered.

Gilat reported Q1 2026 results on May 13 with a 400% earnings beat but a 3.77% revenue miss versus analyst expectations. The company grew revenues 20% year-over-year and more than doubled adjusted EBITDA to $15.1 million, alongside strong operational metrics including margin expansion and military contract wins with India expansion. However, one headline explicitly states the market reaction was driven by high expectations: after the stock tripled in a year, investors wanted better than "fine" results. This is a classic case of a company delivering objectively good fundamentals into an extremely elevated valuation and momentum trade, triggering a sharp profit-taking and sentiment reset. The 21% single-day drop reflects disappointment relative to the outsized prior gains rather than poor absolute performance.

CREG

Smart Powerr Corp.Utilities

$0.20−$0.05

-21.3%

NASDAQ · Mkt cap $499 K

No news headlines were available in the last 48 hours to explain the 21.26% drop in CREG stock. The decline is likely attributable to technical selling, general market weakness in small-cap cleantech stocks, or unreported developments.

Smart Powerr Corp is a micro-cap renewable energy and energy storage company trading at $0.20 per share, placing it at the lower end of market values where volatility is structurally high. With zero news items identified in the most recent two-day window, the reported decline cannot be tied to a specific corporate announcement, earnings release, regulatory action, or sector-wide catalyst visible in the provided data. For stocks in this segment, price declines of this magnitude are commonly triggered by three categories of factors: first, technical selling or stop-loss cascades following an earlier run-up; second, broad liquidity pressures or deleveraging in small-cap equity baskets; and third, company-specific developments—such as financing activity, insider trading, or regulatory issues—that may not yet appear in public headlines or RSS feeds. Without access to intraday volume data, after-hours news, or insider activity, any specific cause remains speculative.

JDZG

JIADE LimitedConsumer Defensive

$1.69−$0.45

-21.0%

NASDAQ · Mkt cap $23 M

JDZG fell 21.03% today, but the provided headlines do not mention the stock or any company-specific catalyst. The sharp decline in a low-priced NASDAQ stock likely reflects either a sector-wide pullback or a stock-specific event not captured in the RSS feed.

The Yahoo Finance article excerpt lists several consumer discretionary stocks with large intraday moves (Robo.ai up 65.2%, Fitness Champs up 53.38%) but does not mention JDZG or any news about JIADE Limited. Without company-specific headlines, the cause cannot be definitively established from the provided data. A 21% single-day loss in a micro-cap stock could result from several common catalysts including deteriorating financial results, shareholder dilution announcements, insider selling, regulatory setbacks, business disruption, or broader market mechanics typical of low-liquidity securities. Absence of news coverage may also reflect the stock's low float or market capitalization, limiting institutional attention.

SST

System1, Inc.Industrials

$3.53−$0.92

-20.7%

NYSE · Mkt cap $22 M

System1 reported a wider quarterly loss and sharp revenue decline in Q1 2026 earnings, triggering a 33% after-hours selloff on May 12 that carried into regular trading on May 13.

The company's first quarter 2026 financial results, announced on the evening of May 12, disclosed both a wider net loss and a significant decline in revenue compared to expectations or prior periods. This double miss—deteriorating profitability combined with shrinking top-line—prompted immediate institutional and retail selling in after-hours trading, with shares falling 33.26% to $2.97. The decline continued into regular trading hours on May 13, where SST closed at $3.53, representing a 20.73% loss for the day. The headlines do not specify the magnitude of the revenue decline or loss widening, nor do they explain management's forward guidance or root causes, but the market's reaction suggests investor confidence in the company's business model was significantly shaken by the earnings miss.

DMIIR

Drugs Made In America Acquisition II Corp. Right

$0.08−$0.02

-20.0%

NASDAQ

No news headlines were found in the past 48 hours, so the 20% drop in this SPAC rights unit is likely driven by either broad market weakness, redemption pressure, or deteriorating deal prospects that have not yet surfaced in public headlines.

DMIIR is a rights unit of a SPAC acquisition vehicle, a security class highly sensitive to deal momentum and redemption risk. The absence of any news in the past 48 hours means the decline was not triggered by a named announcement, regulatory setback, or earnings surprise. For SPACs and their components, typical catalysts include deteriorating business fundamentals of a target company, shareholder redemption pressure ahead of a vote, unfavorable financing terms, or broad sector or market selloff. The sharp 20% move on a rights unit with no concurrent headlines suggests either a technical or liquidity-driven move, or a delayed market reaction to negative information about the SPAC's deal status or target company. Without current headlines, the specific catalyst remains opaque.

EYE

National Vision Holdings, Inc.Consumer Cyclical

$16.92−$4.02

-19.2%

NASDAQ · Mkt cap $1.3 B

National Vision reported Q1 earnings and revenue that beat or met estimates with 6.6% revenue growth and rising EPS, yet the stock fell 19.2%, suggesting the market's positive initial reaction in premarket reversed sharply after examining guidance, margins, or forward commentary on the earnings c…

The available headlines show that National Vision delivered a beat on earnings per share (up to $0.45 from $0.34 year-over-year) and revenue growth of 6.6% to $543.9 million. The premarket reaction was positive, with shares up 5.3% at the open. However, the stock closed down 19.2%, indicating a substantial intraday reversal. The headlines reference management's "transformation plan" and "4 growth vectors," but do not disclose the specific forward guidance, margin trajectories, or management commentary that likely triggered the sell-off. Investors often buy on headline earnings beats but sell during or after earnings calls when guidance is reduced, margin expansion disappoints, or macroeconomic headwinds are outlined. The transcripts are mentioned but their content is not summarized here, leaving the exact driver of the reversal unclear from the evidence provided.

ONEG

OneConstruction Group LimitedIndustrials

$0.85−$0.20

-19.0%

NASDAQ · Mkt cap $16 M

No news headlines were found in the last 48 hours, so the 19% drop cannot be directly attributed to a specific announced event. The decline likely stems from technical selling, delayed news, or market sentiment shifts affecting the micro-cap stock.

The absence of any news in the Yahoo Finance RSS feed over the last 48 hours makes it impossible to link the sharp 19% decline to a concrete catalyst. OneConstruction Group is a micro-cap stock trading at $0.85, which makes it susceptible to outsized moves driven by factors other than major corporate announcements. Possible causes include technical breakdown below a support level, options expiration activity, liquidation pressure, or unfavorable sentiment in the construction sector. Without a specific headline or event to anchor the move, this decline falls into the category of unexplained volatility common in lower-liquidity securities. It is also possible that material news exists but has not yet been picked up by major financial RSS feeds, or that the sell-off reflects intra-week accumulation of negative signals rather than a single trigger.

SDOT

Sadot Group Inc.Consumer Defensive

$0.22−$0.05

-18.9%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours, so the 18.85% decline cannot be directly attributed to a specific announced event; the drop likely reflects either a delayed market reaction to older news, technical selling pressure, or a non-public catalyst.

The absence of any news in the provided 48-hour window makes it impossible to pinpoint a concrete cause for the sharp 18.85% decline in SDOT stock. For a micro-cap or low-priced stock trading at $0.22, moves of this magnitude can be driven by several common factors: thin trading volume amplifying price swings, short covering or momentum-driven selling, delayed reactions to earnings or guidance released outside this news window, sector-wide weakness in whatever industry SDOT operates in, or rumors circulating on social platforms rather than major wire services. Without a specific headline or event identified, any explanation remains speculative. The stock's position as the 28th biggest loser suggests this was a broad-market trading day event rather than an isolated outlier, which might hint at sector or micro-cap sector rotation, but that remains inference without supporting details.

ALBT

Avalon GloboCare Corp.Real Estate

$0.32−$0.07

-17.9%

NASDAQ · Mkt cap $2.9 M

No news headlines were found in the last 48 hours to explain ALBT's 17.93% decline, so the cause remains unclear without additional information about market conditions or company announcements.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for the 17.93% drop in ALBT on May 13, 2026. Avalon GloboCare is a small-cap biotech and healthcare services company, and stocks in this category can be volatile and responsive to various types of events. Possible explanations, offered as inference rather than fact, might include delayed disclosure of earnings or clinical trial results, sector-wide selling pressure in healthcare stocks, technical breakdown following prior strength, institutional position liquidation, or negative commentary from an analyst that hasn't yet propagated to major news feeds. Without concrete information, we cannot distinguish between these possibilities or rule out other catalysts entirely.

REZI

Resideo Technologies, Inc.Industrials

$30.11−$6.57

-17.9%

NYSE · Mkt cap $3.0 B

Resideo crashed 17.91% despite beating Q1 earnings and revenue estimates because management flagged rising supply-chain costs from the Strait of Hormuz closure materially pressuring margins, offsetting revenue growth and overshadowing reaffirmed guidance.

The headline evidence shows Resideo delivered an earnings beat of 7.44% and a revenue beat of 1.99% on May 12, with 8% year-over-year revenue growth to $1.91 billion and reaffirmed 2026 guidance. However, the company disclosed in its Q1 earnings call that closure of the Strait of Hormuz is driving meaningfully higher operating costs that are eroding profit margins despite strong top-line performance. This margin compression appears to have shocked investors, who initially saw the beat as positive but then repriced downward when management quantified the negative cost headwind. The stock's 17.91% single-day drop on May 13 aligns with the May 13 16:12 UTC headline explicitly framing the sell-off around rising costs from the geopolitical disruption. Investors appear to have valued revenue growth less than the threat to profitability, suggesting concerns about near-term margin recovery or management's ability to offset these elevated logistics costs.

SSM

Sono Group N.V. Ordinary SharesConsumer Cyclical

$3.61−$0.79

-17.9%

NASDAQ · Mkt cap $3.8 M

No headlines were reported in the last 48 hours for Sono Group, so the 17.88% drop cannot be attributed to a specific disclosed event. The decline may reflect broader market pressure, technical selling, or undisclosed catalysts.

The absence of recent news headlines for Sono Group makes it difficult to pinpoint a definitive cause for the sharp 17.88% single-day decline. Sono Group is an early-stage solar vehicle technology company, and stocks in this sector are typically sensitive to funding concerns, delays in commercialization timelines, competitive pressures, or shifts in investor sentiment toward speculative EV and cleantech plays. Without disclosed earnings, guidance revisions, partnership announcements, or regulatory developments, the move could reflect general market rotation away from lower-revenue speculative names, technical breakdown below key support levels, or negative information that has not yet been formally announced. Short-interest dynamics and low liquidity in smaller-cap stocks can also amplify single-day moves.

BOT

RoboStrategy, Inc. Common StockFinancial Services

$21.01−$4.39

-17.3%

NASDAQ · Mkt cap $665 M

RoboStrategy stock collapsed 17.28% as speculative fervor cooled after its Nasdaq debut, following multiple trading halts and a sharp initial rally that attracted momentum-driven buyers who subsequently exited.

The headline confirms that BOT experienced a sharp price decline on May 13th following what the news describes as an explosive Nasdaq debut earlier in the week. The stock had surged initially and triggered multiple volatility halts, which typically indicate extreme intraday swings. The news explicitly states that speculative enthusiasm faded Wednesday, suggesting the decline represents a reversal of momentum trading rather than a fundamental business event. This pattern is common in newly listed or recently relisted stocks where retail and speculative capital chases sharp rallies, then exits when momentum stalls. The headline is cut off and provides limited detail on what originally drove the surge, but the explicit reference to fading speculative enthusiasm and post-halt cooling directly explains the observed drop. No earnings, guidance, regulatory, or M&A information is provided.

ZSTK

Flora Growth Corp.Financial Services

$4.44−$0.91

-17.0%

NASDAQ · Mkt cap $32 M

No news headlines were reported in the last 48 hours for ZSTK, so the 17% drop cannot be attributed to a specific announced event. The decline likely stems from technical selling, market-wide pressure, or undisclosed company developments.

The absence of any Yahoo Finance headlines in the last 48 hours means no major earnings announcement, guidance change, regulatory action, or corporate event is visible in the public record provided. Flora Growth Corp. is a cannabis and plant-based products company, a sector historically sensitive to regulatory sentiment, cultivation challenges, supply chain disruptions, and shifts in institutional investor appetite. A drop of this magnitude without visible news could reflect technical momentum reversal, sector-wide selling pressure unrelated to ZSTK-specific catalysts, insider selling, or developments reported through channels not captured in this RSS feed. Without additional context on market-wide cannabis sector performance or company-specific guidance changes, the precise cause remains speculative.

AVIR

Atea Pharmaceuticals, Inc.Healthcare

$4.57−$0.93

-16.9%

NASDAQ · Mkt cap $423 M

Atea reported Q1 2026 earnings and confirmed two Phase 3 hepatitis C trials remain on track for mid-2026 readouts, but the stock fell 16.91%, suggesting investor disappointment with financial results, guidance, or trial expectations despite the operational updates.

On May 12-13, Atea released Q1 2026 financial results and hosted an earnings call. The company confirmed it remains on track for two key Phase 3 hepatitis C readouts in 2026 and is advancing a hepatitis E program for immunocompromised patients. These are positive operational milestones. However, the stock fell sharply, indicating the market reacted negatively to something in the earnings announcement or call. The most likely causes are underwhelming Q1 financial performance (cash burn, revenue miss), reduced guidance, commentary on competitive pressures or trial risk, or investor concern about the timeline and probability of Phase 3 success. The news summaries provided do not detail specific numbers or guidance changes, so the exact source of disappointment cannot be pinpointed from the available headlines alone.

QTI

QT Imaging Holdings, Inc.Healthcare

$6.32−$1.27

-16.7%

NASDAQ · Mkt cap $39 M

QT Imaging reported Q1 2026 revenue of $6.5 million on May 13, triggering a 16.73% stock decline, likely reflecting investor disappointment with financial performance or forward guidance discussed during the earnings call.

QT Imaging released first-quarter 2026 earnings results on May 13, reporting $6.5 million in revenue. The stock dropped sharply on the same day, ranking as the 35th biggest loser on NASDAQ. While the company also announced a positive development—the hiring of Dr. Barry Roseman as Senior Medical Advisor—this appears insufficient to offset negative market reaction to the earnings. The earnings call transcript was published the same day but the headline does not reveal specific details about profitability, margin trends, guidance, or management commentary that might explain the sell-off. For a medical device company at this revenue scale, investors likely reacted to either disappointing earnings metrics, downward guidance, slower-than-expected commercialization pace, or unfavorable commentary on business outlook. Without access to the full earnings transcript or specific financial metrics beyond revenue, the precise cause remains partially obscured.

YIBO

Planet Image International Limited Class A Ordinary SharesTechnology

$0.88−$0.17

-16.2%

NASDAQ · Mkt cap $78 M

No news headlines were found in the last 48 hours, so the 16.25% drop cannot be attributed to a specific disclosed event. The decline likely reflects technical selling, broader market weakness, or undisclosed company developments.

The absence of any news in the Yahoo Finance RSS feed within 48 hours of this sharp 16.25% decline means we cannot point to a specific catalyst such as earnings, guidance, regulatory action, or corporate announcements. For a small-cap stock like Planet Image International (trading at $0.88), price declines of this magnitude can result from several common drivers: thin liquidity and technical selling pressure, sector rotation or broader market downturns affecting micro-cap equities, short-term speculative reversals, or delayed disclosure of negative developments that may not yet have reached major news feeds. Without access to real-time trading data, SEC filings, or company press releases beyond the provided headlines, identifying the precise cause remains speculative.

PHOE

Phoenix Asia Holdings Limited Ordinary SharesIndustrials

$15.08−$2.92

-16.2%

NASDAQ · Mkt cap $526 M

No news headlines were found in the last 48 hours, so the 16.22% drop likely reflects a delayed earnings announcement, sector-wide selloff, or unreported company-specific event that has not yet reached major financial news wires.

Phoenix Asia Holdings Limited experienced a sharp 16.22% single-day decline while ranking among the day's 37 biggest losers, yet no recent news headlines appear in the Yahoo Finance RSS feed for the past 48 hours. This disconnect between significant price action and absent headline coverage suggests several possibilities. The move could reflect a delayed or after-hours earnings release that has not yet propagated to headline aggregators, a sector-specific downturn affecting Asia-focused equities without individual company coverage, or an internal announcement (such as guidance revision, insider selling, or corporate action) released through investor relations channels before broader media pickup. Without access to the company's official filings or press releases, it is not possible to pinpoint the precise catalyst. Hong Kong-listed or Asia-focused companies sometimes experience delayed information dissemination to US-based financial news aggregators, which could explain the price decline without concurrent headline visibility.

PTN

Palatin Technologies, Inc.Healthcare

$16.55−$3.16

-16.0%

AMEX · Mkt cap $18 M

Palatin reported Q3 2026 financial results and held an earnings call on May 13, likely triggering the 16% decline, though the specific financial details or guidance that disappointed are not disclosed in the headlines provided.

Palatin Technologies, a biopharmaceutical company focused on melanocortin receptor therapies, released fiscal Q3 2026 earnings and held a conference call on the same day. The timing of the 16% drop coinciding with earnings announcement strongly suggests the market reacted negatively to disclosed results or forward guidance. However, the headlines provided only confirm that earnings were reported and a call occurred; they do not detail the actual financial metrics, losses, drug development milestones, cash position, or management guidance that would explain investor disappointment. For a pre-revenue or early-stage biotech company like Palatin, typical sell-triggers include cash burn rates, delayed trial results, missed clinical milestones, or reduced runway guidance. Without access to the earnings transcript content or the actual financial results document, the specific cause remains inference rather than fact.

SWMR

Swarmer, Inc Common StockTechnology

$30.29−$5.75

-16.0%

NASDAQ · Mkt cap $452 M

Swarmer reported a sharp year-over-year revenue decline in its first earnings call as a public company on May 13, which likely triggered the 16% sell-off despite simultaneous announcements of new contracts worth up to $13.2 million.

Swarmer released first-quarter 2026 financial results on May 13 and disclosed a significant revenue decline year-over-year during its inaugural earnings call as a public company. This negative revenue trend appears to have dominated investor sentiment despite the company simultaneously announcing a $2.86 million contract with Meta Bureau LLC (with options for up to $13.2 million) and leading development of a drone interceptor system. The disconnect suggests investors are focused on the deteriorating top-line performance rather than future contract potential. For an early-stage defense technology company, particularly one newly public, a sharp revenue decline may signal slower customer adoption, execution challenges, or margin pressures that concern growth-oriented investors, even when backlog or contract wins are announced alongside the results.

HUBC

HUB Cyber Security Ltd.Technology

$0.15−$0.03

-15.7%

NASDAQ · Mkt cap $23 M

No news headlines were found in the last 48 hours, so the 15.72% decline cannot be attributed to a specific announced event; the drop likely reflects technical selling, market-wide pressure, or delayed reaction to prior news.

The absence of any recent news headlines within the last 48 hours means we cannot point to earnings misses, product announcements, regulatory actions, or guidance changes as the direct cause of this substantial single-day loss. For a micro-cap security trading at $0.15, price moves of this magnitude often occur on limited volume and can be driven by several unstated factors: technical chart breaks below support levels, sector rotation out of cybersecurity names, general sell-offs in lower-priced equities, or delayed market reaction to news released earlier than 48 hours ago. Without access to intraday volume data, short interest levels, or prior-week announcements, we cannot determine whether this reflects fundamental deterioration or tactical repositioning. The stock's position as the 40th biggest loser suggests it is not an isolated move but part of a broader market pattern.

GAUZ

Gauzy Ltd. Ordinary SharesTechnology

$0.79−$0.14

-15.1%

NASDAQ · Mkt cap $6.9 M

No news headlines were found in the last 48 hours, so the 15% drop in GAUZ likely stems from technical selling, broader market conditions, or unreported developments in the micro-cap optical materials space.

The absence of any news in the Yahoo Finance RSS feed over the last 48 hours means we cannot anchor the decline to a specific catalyst such as earnings, guidance, a contract loss, or regulatory action. Gauzy Ltd is a small-cap NASDAQ-listed company in advanced optical materials and smart glass technology, sectors that can be volatile and subject to liquidity constraints. A 15% single-day drop on a stock trading at $0.79 could reflect several possibilities: profit-taking after a prior run, a missed analyst expectation that hasn't yet appeared in aggregated headlines, short covering or forced liquidation, or a negative development reported through channels not captured by the RSS feed. Without supporting news, we cannot distinguish between these scenarios. Micro-cap technology stocks are particularly susceptible to momentum reversals and thin-volume shocks.

RPGL

Republic Power Group Limited Class A Ordinary SharesTechnology

$0.38−$0.07

-15.1%

NASDAQ · Mkt cap $2.6 M

No news specifically about RPGL was provided; the 15% drop likely reflects broader sector pressure, a delayed negative announcement, or technical selling in a micro-cap stock with low liquidity.

The single headline provided discusses Cisco and other information technology gainers in after-market trading on Wednesday, which is unrelated to Republic Power Group. RPGL operates in a different sector and there are no earnings releases, guidance changes, regulatory actions, or company-specific announcements cited in the available news feed. For a micro-cap stock trading at $0.38, sharp single-day moves are common absent major catalysts due to low trading volume and liquidity. The drop could stem from delayed SEC filings, insider selling, sector rotation away from power or utility stocks, or technical support breaking on a chart. Without company-specific news, the cause remains speculative.

TWAV

TaoWeave, Inc.Financial Services

$1.41−$0.25

-15.1%

NASDAQ · Mkt cap $4.9 M

No news headlines were found in the last 48 hours for TWAV, so the 15% intraday drop likely reflects either technical selling pressure, sector rotation, or undisclosed company-specific developments that have not yet reached major financial news outlets.

TaoWeave Inc. experienced a sharp 15.06% decline on May 13, 2026, ranking as the 43rd biggest loser that day. However, no recent news articles were published on Yahoo Finance in the preceding 48 hours to explain this move. This absence of reported news makes it difficult to pinpoint a specific catalyst. The drop could be driven by several plausible but unconfirmed mechanisms: technical liquidation following a previous rally, broad-based sector selloff affecting micro-cap or technology stocks, margin calls or short covering, or a material company announcement that has not yet been picked up by major news feeds. Without access to intra-day trading data, company filings, or social media sentiment, the true driver remains unknown. Small-cap stocks like TWAV are often more susceptible to volatile moves on light volume or retail trading activity.

APPX

Tradr 2X Long APP Daily ETF

$33.58−$5.92

-15.0%

NASDAQ

No news headlines were found in the last 48 hours, but APPX is a 2X leveraged ETF tracking APP, so a sharp 15% drop likely reflects an underlying decline in APP shares amplified by the 2X daily reset mechanism.

The absence of any news in the last 48 hours means we cannot point to a specific catalyst such as earnings, guidance, or corporate action. However, APPX's structure as a 2X long daily leveraged ETF is material to interpreting this move. Leveraged ETFs are designed to deliver twice the daily return of their underlying index or security; they reset daily, which means they experience decay in volatile sideways markets but will amplify sharp single-day moves in either direction. A 15% loss in APPX suggests the underlying APP asset fell roughly 7-8% on the day. Without news, the cause of APP's decline could range from broad market selloff, sector rotation, technical breakdown, or company-specific issues not yet captured in available headlines. Additional reporting lag or delayed disclosure is possible.

RCAT

Red Cat Holdings, Inc.Industrials

$9.40−$1.63

-14.8%

NASDAQ · Mkt cap $1.3 B

Red Cat announced a $225 million public stock offering priced at a 15% discount to the previous closing price, triggering a sharp selloff due to immediate shareholder dilution and the market's signal that the company needs cash to cover ongoing losses.

Red Cat Holdings announced the pricing of a $225 million public offering on May 12–13, 2026, at a 15% discount to the last closing price. This is the primary catalyst for the 14.78% decline. A discounted secondary offering signals two concerns to the market: first, immediate dilution to existing shareholders' ownership stake, and second, implicit acknowledgment by management that the company requires capital to sustain operations. The news explicitly noted that Red Cat "keeps burning" cash, reinforcing investor concerns about the company's cash burn rate. While Needham reiterated a Buy rating following Q1 2026 results on May 13, that positive analyst action appears insufficient to offset the negative sentiment from the heavily discounted equity raise, which typically pressures stock price on announcement and through the offering period.

ACCS

ACCESS Newswire Inc.Communication Services

$6.93−$1.18

-14.5%

AMEX · Mkt cap $19 M

ACCESS Newswire posted a Q1 earnings beat with strong customer metrics (revenue down 4.71% but earnings up 22.22%), yet the stock fell 14.55%, suggesting the revenue decline and forward guidance concerns outweighed the earnings surprise.

ACCESS reported mixed Q1 results on May 12: earnings per share beat estimates by 22.22%, while revenue missed by 4.71%. Management highlighted increased average ARR per customer ($12,803, up from $11,139 year-over-year) and positive adjusted EBITDA, signaling operational leverage and customer quality improvement. However, the absolute revenue decline appears to have triggered selling despite the earnings beat, possibly because investors view top-line contraction as a red flag for future growth even if profitability metrics look strong. The stock may also be sensitive to forward guidance or commentary during the earnings call that cast doubt on revenue stabilization. Without access to the full earnings transcript or any guidance revision announcements, the exact catalyst remains partially unclear, but the tension between earnings beats and revenue decline is the most plausible explanation for the sharp drop.

MTC

MMTec, Inc.Financial Services

$5.27−$0.89

-14.4%

LSH

Lakeside Holding LimitedIndustrials

$0.57−$0.09

-14.3%

NASDAQ · Mkt cap $18 M

LSH fell 14.33% on May 13 with no news reported in the last 48 hours, making the specific catalyst unclear and likely attributable to broad market weakness, technical selling, or undisclosed corporate developments.

No headlines were found in the last 48 hours to explain the 14.33% drop in LSH. Without news anchoring the move, the decline could reflect several possibilities. First, the stock may have experienced technical selling pressure—a micro-cap trading at $0.57 is sensitive to thin liquidity and momentum-driven exits. Second, there may be an undisclosed or delayed announcement not yet captured in the headline feed, such as disappointing earnings, regulatory action, or insider selling. Third, sector-wide weakness or a broad market decline on May 13 could have dragged down a lower-conviction holding. Without supporting evidence from news or corporate filings, attributing the move to a specific event would be speculation rather than analysis.

WFCF

Where Food Comes From, Inc.Industrials

$11.01−$1.84

-14.3%

NASDAQ · Mkt cap $62 M

WFCF dropped 14.32% on May 13, likely driven by negative earnings expectations or disappointing Q1 2026 results announced or previewed on May 12, coinciding with the company's earnings call scheduling.

Where Food Comes From scheduled its Q1 2026 earnings call on May 12, which typically precedes or accompanies earnings release. The 14% single-day decline on the following trading day suggests investors reacted negatively to either the earnings announcement itself, forward guidance, or negative pre-release signaling. The only substantive news in the 48-hour window is the earnings call announcement and a positive update about US Agrichar's biochar certification. The biochar news appears unrelated to the drop, as it represents a milestone achievement for a portfolio company. The timing and magnitude of the decline strongly point to earnings disappointment or guidance reduction as the primary driver. Without access to the actual Q1 results or call transcript, we cannot confirm specific metrics that disappointed (revenue, margins, subscriber counts, etc.), but the near-certain catalyst was earnings-related.

AII

American Integrity Insurance Group, Inc.Financial Services

$16.87−$2.73

-13.9%

NYSE · Mkt cap $470 M

American Integrity Insurance reported Q1 2026 earnings on May 12-13 showing net income and EPS both declined sharply year-over-year, likely triggering the 13.93% stock decline.

The headlines establish that American Integrity released Q1 2026 financial results showing net income of $19.9 million or $1.02 per diluted share, down significantly from $35.9 million or $2.78 per share in the prior-year quarter. This represents a 45% decline in net income and a 63% decline in diluted EPS. Multiple earnings-related articles were published on May 12-13, with the official earnings release on May 12 followed by earnings call transcripts and summaries on May 13. The timing aligns precisely with the stock's largest single-day decline. While the specific reasons for the earnings miss are not detailed in the headlines provided, insurance companies typically face margin pressure from elevated claims, reserve adjustments, or underwriting losses, particularly for property-casualty insurers operating in hurricane-prone regions like Florida. The magnitude of the EPS decline relative to net income decline suggests either a reduction in share count or other structural factors at play.